FDG PET/CT for Liver Cancer

A major new literature review is adding weight to something imaging specialists have long suspected: FDG PET/CT for liver cancer isn't just a detection tool—it's a meaningful predictor of how patients with hepatocellular carcinoma (HCC) will fare.

According to a study published in JHEP Reports and covered by AuntMinnie.com, pretreatment F-18 FDG-PET/CT scans were positive in nearly one-third of HCC patients (30.8%) and were significantly associated with patient outcomes across three survival measures. The systematic review and meta-analysis encompassed 59 studies and more than 8,500 patients—making it one of the most comprehensive analyses of this topic to date.

Researchers analyzed studies that linked pretreatment FDG-PET/CT findings to overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS) in HCC patients.

The results were consistent and striking: elevated FDG uptake was associated with significantly worse outcomes across all three metrics—with hazard ratios of 2.05 for OS, 3.18 for RFS, and 1.64 for PFS. Critically, the prognostic value held whether patients received curative or non-curative treatment, and across multiple PET/CT measurement methods including SUVmax, tumor-to-liver ratio, and visual assessment.

The authors concluded that these findings support the scan's prognostic relevance in HCC, while calling for further studies to standardize parameters and identify the settings where it provides the greatest incremental value for treatment planning and risk stratification.

Hepatocellular carcinoma is one of the most aggressive and prevalent malignancies worldwide. Despite advances in treatment, five-year survival rates for advanced-stage HCC remain below 20%. Any tool that can help physicians more accurately stratify risk and tailor treatment plans earlier in the process has real potential to change outcomes.

What makes FDG PET/CT especially valuable here is its ability to detect metabolic changes in cancer cells before structural changes are visible on traditional imaging. As explained on our PET/CT page, PET can detect biochemical changes in an organ or tissue that can identify the onset of a disease process before anatomical changes related to the disease can be seen with other imaging processes. When combined with CT's precise anatomical localization, the result is a uniquely comprehensive picture of disease activity.

Physicians commonly use PET/CT to:

• Differentiate malignant from non-malignant disease (diagnosis)
• Determine whether a cancer has spread in the body (staging)
• Assess the effectiveness of a treatment plan, such as cancer therapy (response to therapy)
• Determine if a cancer has returned after treatment (restaging)

This new HCC research reinforces that PET/CT's role extends beyond these traditional indications—into prognosis itself.

The tracer at the heart of this research—F-18 FDG (fluorodeoxyglucose)—is the same specialized radiotracer used in FDG PET/CT Scan for Cancer Imaging. Because cancer cells are more metabolically active than normal cells, they absorb more FDG—a property that allows physicians to identify abnormal activity throughout the body, often earlier and with greater precision than conventional imaging alone.

By combining PET (which shows how cells are functioning at the metabolic level) with CT (which pinpoints the exact anatomical location of abnormalities), the scan delivers what the researchers in this HCC study relied on: a window into tumor biology, not just tumor location.

Beyond gastrointestinal cancers like HCC, FDG PET/CT is used to evaluate a broad range of malignancies—from lung and lymphoma to ovarian, cervical, and breast cancers—making it one of the most versatile tools in oncologic imaging.

For referring physicians treating patients with HCC or other cancers requiring advanced staging and prognostic evaluation, Capitol Imaging Services offers FDG PET/CT scan for cancer imaging at multiple locations across the Gulf South region.

Outpatient imaging at Capitol Imaging Services centers typically comes at a significantly lower cost than hospital-based alternatives—without sacrificing image quality or the expert radiology interpretation that complex oncology cases demand.

As the evidence base continues to grow—now including its role as a prognostic biomarker in liver cancer—the case for broader clinical adoption of FDG PET/CT grows with it.